Clinical trial · Interventional
Hybrid Endoscopic Hemithyroidectomy and Targeted Ablation for Bilateral Papillary Thyroid Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study evaluates a thyroid-function-preserving alternative to routine total thyroidectomy for bilateral papillary thyroid carcinoma (PTC). Eligible adults undergo remote-access gas-less axillo-breast endoscopic hemithyroidectomy with level VI dissection on the dominant side, followed by ultrasound-guided radiofrequency ablation (RFA) of a ≤7 mm contralateral focus during the same anesthesia. Outcomes include structural-recurrence-free survival, endocrine-function preservation, safety, and quality of life over 24 months.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Papillary | Papillary Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Thyroid Neoplasms | Thyroid Gland Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Endoscopic Hemithyroidectomy with Central-Neck Dissection | Procedure | — | UNRESOLVED |
| Ultrasound-Guided Radiofrequency Ablation of Contralateral Nodule | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Hybrid Endoscopic Hemithyroidectomy + Same-Session Contralateral RFA
- description
- Remote-access gas-less axillo-breast endoscopic hemithyroidectomy with level VI central-neck dissection on the dominant lobe, immediately followed-under the same anesthesia-by ultrasound-guided radiofrequency ablation (17-G, 0.7 cm active tip, 40 W, moving-shot technique) of a ≤ 7 mm contralateral papillary thyroid microcarcinoma.
- interventionNames
- Procedure: Endoscopic Hemithyroidectomy with Central-Neck Dissection
- Procedure: Ultrasound-Guided Radiofrequency Ablation of Contralateral Nodule
Primary outcomes (2)
- measure
- Structural Recurrence-Free Survival
- timeFrame
- 24 months
- description
- Proportion of participants without local, regional, or distant structural recurrence confirmed by imaging ± cytopathology.
- measure
- Endocrine-Function Preservation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18-65 years. * Dominant-side PTC ≤1.5 cm suitable for endoscopic resection. * Contralateral nodule ≤7 mm located ≥2 mm from posterior capsule. * No radiologic lymph-node metastasis on contralateral side. * Written informed consent. Exclusion Criteria: * Extrathyroidal extension, gross nodal or distant metastasis. * Prior neck surgery, prior RFA/ethanol injection, or neck irradiation. * Pregnancy or lactation. * Serious comorbidities precluding anesthesia or follow-up.
References
Publications (0)
Data not yet available